Advertisement

Topics

sanofi-aventis U.S. LLC Company Profile

04:54 EDT 25th September 2018 | BioPortfolio


News Articles [681 Associated News Articles listed on BioPortfolio]

sanofi-aventis’ New Direction

Since Chris Viehbacher joined sanofi-aventis as CEO his aim has been to get the company recognised as a global healthcare company and not solely as a producer of vaccines. Jean-Claude Muller, Senior V...

#jobs #lifescience Sanofi-Aventis: Director, Global Regulatory Team Lead

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sanofi-Aventis: Director, Global Regulatory Team Lead . Competitive Salary: S...

Epistem announces collaboration with Sanofi Aventis

Epistem plc, the UK biotechnology and personalised medicine company today announced a collaboration with sanofi-aventis U.S. Inc. relating to the use of Epistem's proprietary biomarker gene expression...

The Transformation Of Sanofi-Aventis U.S.

The exclusive Life Science Leader interview with Gregory Irace, president and CEO of sanofi-aventis U.S. By Dan Schell, Life Science Leader magazine

Royalties under patent licence agreements: can they remain payable even if the licensed patents(s) are revoked or not practised? Lessons from Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH

Précis In its recent decision in Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH (7 July 2016), the Court of Justice of the EU (“CJEU”) has ruled that an obligati...

Deutsche Bank senkt Ziel für Sanofi auf 87 Euro - 'Buy'

Die Deutsche Bank hat das Kursziel für Sanofi von 88 auf 87 Euro gesenkt, aber die Einstufung auf "Buy" belassen. Der Zusammenschluss von Sanofi und Aventis habe in den vergangenen zehn Jahren krä.....

Dyadic International Announces Research Collaboration with Sanofi-Aventis

JUPITER, Fla., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C...

Animal Health JV, PTV News: Mar 09, 2010

Merck & Co. and sanofi-aventis target US$ 19B market

PubMed Articles [8 Associated PubMed Articles listed on BioPortfolio]

Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes.

To study the safety and efficacy of intravitreal injections of ziv-aflibercept (IVI-ZA) (Zaltrap; Sanofi-Aventis and Regeneron Pharmaceuticals, Tarrytown, NY) during a period of 48 weeks in patients w...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Dupixent, a New Entrant In the Asthma Lists.

Sanofi and Regeneron's Dupixent (dupilumab)-which is already approved for atopic dermatitis-has an FDA action date of October 20 for its asthma indication. It will join Nucala, (mepolizumab), Cinqair ...

Imidazopyrazinones (IPYs): non-quinolone bacterial topoisomerase inhibitors showing partial cross-resistance with quinolones.

In our quest for new antibiotics able to address the growing threat of multi-drug resistant infections caused by Gram-negative bacteria, we have investigated an unprecedented series of non-quinolone b...

Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning.

CYD-TDV is the first licensed dengue vaccine for individuals 9-45 (or 60) years of age. Using 12% of the subjects enroled in phase-2b and phase-3 trials for which baseline serostatus was measured, the...

Clinical Trials [97 Associated Clinical Trials listed on BioPortfolio]

A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects

The purpose of this study is to determine bioequivalence of amodiaquine suspension ( Pfizer) and the WHO approved reference product Flavoquine® tablet ( Sanofi Aventis).

Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)

SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as antith...

: Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery

To evaluate the pharmacokinetics of the thromboprophylactic agent enoxaparin in postoperative cardiac surgery patients by comparing plasma anti-Xa activity when enoxaparin is administered ...

A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis

A randomized, double-blind, placebo-controlled parallel-group study, comparing the bioequivalence of triamcinolone acetonide aqueous nasal spray (Apotex, Inc.) to that of Nasacort® AQ nas...

A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia

The primary objective of the study is to determine whether eszopiclone (Eurofarma) is non-inferior to the reference drug zopiclone (Imovane®, Sanofi-Aventis) in the treatment of insomnia.

Companies [78 Associated Companies listed on BioPortfolio]

sanofi-aventis U.S.

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. San...

Bristol-Myers Squibb & Sanofi-aventis

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the l...

Sanofi Aventis Groupe

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SA...

Merck and sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Pa...

Sanofi SA

Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales.

More Information about "sanofi-aventis U.S. LLC" on BioPortfolio

We have published hundreds of sanofi-aventis U.S. LLC news stories on BioPortfolio along with dozens of sanofi-aventis U.S. LLC Clinical Trials and PubMed Articles about sanofi-aventis U.S. LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of sanofi-aventis U.S. LLC Companies in our database. You can also find out about relevant sanofi-aventis U.S. LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record